Concerns over the controversial EU guideline on good manufacturing practice requirements for advanced therapy medicinal products (ATMPs) have prompted the regulatory authorities participating in the international Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the World Health Organization to create a new working group to suggest possible solutions.
Regulators around the world are worried about divergences between the EU GMP ATMP guideline, which was finalized last year, and the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?